Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 7304 results found since Jan 2013.
Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults - United States, December 2020-March 2023
This report includes analysis of data on self-reported symptoms collected from 1,296 adults with COVID-like illness who were tested for SARS-CoV-2 using a Food and Drug Administration-approved polymerase chain reaction or antigen test at the time of enrollment and reported symptoms at 3-month intervals for 12 months. Prevalence of any symptom decreased substantially between baseline and the 3-month follow-up, from 98.4% to 48.2% for persons who received a positive SARS-CoV-2 test results (COVID test-positive participants) and from 88.2% to 36.6% for persons who received negative SARS-CoV-2 test results (COVID test-negative...
Source: MMWR Morb Mortal Wkl... - August 10, 2023 Category: Epidemiology Authors: Juan Carlos C Montoy James Ford Huihui Yu Michael Gottlieb Dana Morse Michelle Santangelo Kelli N O'Laughlin Kevin Schaeffer Pamela Logan Kristin Rising Mandy J Hill Lauren E Wisk Wafah Salah Ahamed H Idris Ryan M Huebinger Erica S Spatz Robert M Rodrigue Source Type: research
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week
J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.ABSTRACTAmong statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular even...
Source: Atherosclerosis - August 9, 2023 Category: Cardiology Authors: Kyle Nelson Valentin Fuster Paul M Ridker Source Type: research
A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
J Drugs Dermatol. 2023 Aug 1;22(8):761-765. doi: 10.36849/jdd.7481.ABSTRACTPsoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque psoriasis. With proven efficacy and safety, topical corticosteroids are often used, although adverse effects and limitations for use exist. Tapinarof (Vtama®), a novel topical aryl hydrocarbon receptor modulating drug, was approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults in May 2022. A literature search ...
Source: Journal of Drugs in Dermatology - August 9, 2023 Category: Dermatology Authors: Julie Kalabalik-Hoganson Anna Nogid Kathleen Frey Source Type: research
